81131-74-0

Basic information

• Product Name: (3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutano yl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid
• Synonyms: (3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutano yl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid
• CAS NO: 81131-74-0
• Molecular Formula: C₂₃H₃₆O₇
• Molecular Weight: 424.52774
• Mol File: 81131-74-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 640.3°Cat760mmHg
• Flash Point: 215.5°C
• Appearance: /
• Density: 1.21g/cm³
• Vapor Pressure: 4.3E-19mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: (3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutano yl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutano yl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid(81131-74-0)
• EPA Substance Registry System: (3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutano yl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid(81131-74-0)

Safety Data

• Hazardous Substances Data: 81131-74-0(Hazardous Substances Data)

Usage

General Description

The chemical "(3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoic acid" is a complex organic compound composed of a hexahydronaphthalene ring and a heptanoic acid chain. It has a stereochemistry with two chiral centers, denoted as 3R and 5R, and contains hydroxyl and carboxylic acid functional groups. The compound also contains a methylbutanoyl group attached to the hexahydronaphthalene ring. This chemical structure suggests that it may have potential biological activity or pharmaceutical properties, and therefore, may be of interest for further study in the fields of medicine and drug discovery.

InChI:InChI=1/C23H36O7/c1-4-13(2)23(29)30-20-7-5-6-15-10-19(26)14(3)18(22(15)20)9-8-16(24)11-17(25)12-21(27)28/h5-6,10,13-14,16-20,22,24-26H,4,7-9,11-12H2,1-3H3,(H,27,28)/t13-,14+,16+,17+,18-,19+,20-,22-/m0/s1

Upstream product

• 81131-70-6 pravastatin sodium salt 
• 73573-88-3 mevastatin 
• 84173-31-9 3,5-bis-epi-compactin 

Downstream Products

• 85956-22-5 pravastatin lactone 
• 81131-70-6 pravastatin sodium salt 
• 81131-70-6 Sodium; 3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methyl-butyryloxy)-1,2,6,7,8,8a-hexahydro-naphthalen-1-yl]-heptanoate 
• 135716-16-4 (S)-2-Methyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-3-hydroxy-7-methyl-decahydro-naphthalen-1-yl ester 
• 136491-73-1 (S)-2-Methyl-butyric acid (1S,4aS,7S,8S,8aS)-8-(2-{(4R,6S)-6-[2-(tert-butyl-diphenyl-silanyloxy)-ethyl]-2,2-dimethyl-[1,3]dioxan-4-yl}-ethyl)-7-methyl-3-oxo-decahydro-naphthalen-1-yl ester 
• 135716-15-3 (S)-2-Methyl-butyric acid (1S,3R,4aS,7S,8S,8aS)-8-[(3R,5S)-7-(tert-butyl-diphenyl-silanyloxy)-3,5-dihydroxy-heptyl]-3-hydroxy-7-methyl-decahydro-naphthalen-1-yl ester 

Relevant articles and documents

He the sandbank contains the fluorine derivative and use thereof

The present invention belongs to the field of pharmaceutical chemistry, and provides 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, wherein a fragment containing 3-fluoro-caprolactone and a lactone thereof are subjected to ring opening to form a poly-substituted pyrimidine statin fluorine-containing modifier of 1-fluoro-3-hydroxy-pentanoic acid and a salt or ester thereof, ie., the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor, and the structure formula is defined in the specification. According to the present invention, the test results show that the compounds have the HMG-CoA reductase activity inhibition effects, and can be used as the new generation of the potential HMG-CoA reductase inhibitors.

In situ bioconversion of compactin to pravastatin by Actinomadura species in fermentation broth of Penicillium citrinum

The biocatalytic production of pravastatin from compactin by hydroxylation has found many applications in health care and pharmaceuticals. Actinomadura macra, Actinomadura madurae, and Actinomadura livida can efficiently bioconvert compactin to pravastatin. The fermentation broth (Penicillium citrinum fermented media) harvested on the eighth day contained 388.90 mg L-1 of compactin and an undetectable level of mycotoxin (citrinin). Bioconversion by A. macra was highest (87 %) in the yeast extract-amended medium. The anti-actinomadura effects of citrinin reduce the bioconversion capacity of Actinomadura. The in situ hydroxylation of compactin produced by P. citrinum represents a preferable alternative for the use of purified compactin, as a way to reduce cost and time processing.

Drug or Supplement Combination with Conjugated Linoleic Acid for Fat Loss in Mammals

Food, feed or drug combinations with conjugated linoleic acid are described that cause enhanced fat loss in mammals more efficiently than any of the individual components of the combination. Food, feed, or drugs that activate AMP activated protein kinase, agonists of nuclear receptors that bind RXR in adipocytes, or statin inhibitors were found to be more effective for fat loss when combined with conjugated linoleic acid.